Posted by Michael Wonder on 09 Jan 2020
Aruvant receives FDA rare paediatric disease designation for ARU-1801 for the treatment of sickle cell disease
8 January 2020 - ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassaemia.
Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercialising transformative therapies for the treatment of severe blood disorders, today announced that the U.S. FDA has granted rare paediatric disease designation to ARU-1801, Aruvant's investigational therapy for the treatment of sickle cell disease.
With this designation, Aruvant will be eligible to receive a priority review voucher upon approval by the FDA of a Biologics License Application for ARU-1801.
